Search Results 601-610 of 24240 for In situ

1. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis - Mayo Clinic

   History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ ... Any serious medical condition or abnormality in ...

2. Publications - Miglena K. Komforti, D.O. - Mayo Clinic

   Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.

3. A Clinical Study To Test How Effective And Safe GLPG1690 Is For Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment

   ... In Situ). Clinically significant abnormalities detected on ECG of either rhythm or conduction, a QTcF > 450 ms, or a known long QT syndrome. Currently ...

4. Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients - Mayo Clinic

   ... in a trial will be enrolled. Contact the study team to ... Risk of venous occlusion or lesion precluding implant (e.g., multiple existing leads in situ); ...

5. Breast cancer - Doctors and departments - Mayo Clinic

   ... situ, Recurrent breast cancer, Inflammatory ... in situ, Atypical hyperplasia of the breast, HER2 ... Mayo Clinic in Rochester, Minnesota, Mayo Clinic in ...

6. A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression - Mayo Clinic

   Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of ...

7. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

   * Adequately treated lobular carcinoma in situ or ductal carcinoma in situ considered to have a very low risk of recurrence * Localized prostate cancer (T1c ...

8. MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery - Mayo Clinic

   ... in-situ of the cervix; NOTE: if there is a history of prior malignancy > 5 years prior to registration, the patient must not be receiving other cancer treatment ...

9. Breast Cancer Surgery Program in Jacksonville - Conditions treated - Mayo Clinic

   Ductal carcinoma in situ (DCIS); Estrogen receptor positive breast cancer; Fibroadenoma · Galactorrhea; Genetic predisposition to breast cancer; HER2-positive ...

10. Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma - Mayo Clinic

    ... in situ of any type. Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone ...